CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionPrice-to-book is 0.62×, lower than 95% of its Medical Devices peers (median 2.69×)
- FinancialsAltman Z-Score -1.32: distress zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
350.32MUSDvs all stocks (USD)
Revenue (TTM)
86.25MUSDvs all stocks (USD)
Beta
1.42xvs all stocks
52-Week Change
-29.37%vs all stocks
Market Capitalization
350.32MUSDvs all stocks (USD)
Enterprise Value
-76.34MUSDvs all stocks (USD)
Forward P/E
-89.49xvs Medical Devices peers
Price to Sales (TTM)
4.06xvs Medical Devices peers
Price to Book (MRQ)
0.6223xvs Medical Devices peers
Enterprise to Revenue
-0.8850xvs Medical Devices peers
Enterprise to EBITDA
1.12xvs Medical Devices peers
Gross Margin
53.48%vs Medical Devices peers
Operating Margin
-44.53%vs Medical Devices peers
Return on Assets (TTM)
-8.05%vs Medical Devices peers
Return on Equity (TTM)
-9.86%vs Medical Devices peers
Revenue (TTM)
86.25MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2250USDUpdated Jul 19, 2026Quarterly Revenue Growth
4.60%vs Medical Devices peers
Gross Profit (TTM)
45.95MUSDvs all stocks (USD)
EBITDA (TTM)
-68.21MUSDvs all stocks (USD)
Net Income (TTM)
-50.08MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-48.17%vs Medical Devices peers
Operating Cash Flow (TTM)
-90.66MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-13.44MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
85.33MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
42.79MUSDFY2025 · Dec 31, 2025Gross Profit
42.54MUSDFY2025 · Dec 31, 2025Operating Income
-93.31MUSDvs all stocks (USD)
Pre-tax Income
-96.70MUSDFY2025 · Dec 31, 2025Income Tax Expense
-37.88MUSDFY2025 · Dec 31, 2025Net Income
-74.90MUSDFY2025 · Dec 31, 2025EBIT
-96.68MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-68.75MUSDFY2025 · Dec 31, 2025Research & Development
25.99MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
109.86MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
9.18MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
26.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.2000USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.2000USDFY2025 · Dec 31, 2025Basic Shares Outstanding
381.62MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
381.62MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-74.90MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-87.04MUSDFY2025 · Dec 31, 2025Free Cash Flow
-95.34MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
123.30MUSDFY2025 · Dec 31, 2025Interest Paid
15.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-74.90MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
10.98MUSDFY2025 · Dec 31, 2025Stock-based Compensation
29.61MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.75MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-39.45MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.44MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-19.46MUSDFY2025 · Dec 31, 2025Capital Expenditures
-8.30MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-138.29MUSDFY2025 · Dec 31, 2025Sale of Investments
179.00MUSDFY2025 · Dec 31, 2025Other Investing Activity
-5.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
27.41MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-484.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-484.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
390.14MSharesUpdated Jul 19, 2026Float Shares
209.46MSharesUpdated Jul 19, 2026Shares Short
3.43MSharesUpdated Jul 19, 2026Short Ratio
0.5800daysvs all stocks
Short % of Shares Outstanding
1.45%vs all stocks
% Held by Insiders
1.69%vs all stocks
% Held by Institutions
76.78%vs all stocks
Total Cash (MRQ)
455.18MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.17USDUpdated Jul 19, 2026Total Debt (MRQ)
29.49MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0526xvs Medical Devices peers
Current Ratio (MRQ)
12.36xvs Medical Devices peers
Book Value per Share (MRQ)
1.44USDUpdated Jul 19, 2026Total Assets
567.75MUSDvs all stocks (USD)
Total Current Assets
454.26MUSDFY2025 · Dec 31, 2025Total Liabilities
143.46MUSDFY2025 · Dec 31, 2025Total Non-current Assets
113.49MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
35.16MUSDFY2025 · Dec 31, 2025Total Current Liabilities
108.31MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
120.86MUSDFY2025 · Dec 31, 2025Other Short-term Investments
66.71MUSDFY2025 · Dec 31, 2025Accounts Receivable
13.43MUSDFY2025 · Dec 31, 2025Inventory
19.98MUSDFY2025 · Dec 31, 2025Accounts Payable
5.41MUSDFY2025 · Dec 31, 2025Short-term Debt
5.49MUSDFY2025 · Dec 31, 2025Deferred Revenue
42.94MUSDFY2025 · Dec 31, 2025Other Current Liabilities
25.63MUSDFY2025 · Dec 31, 2025Long-term Debt
25.34MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.22MUSDFY2025 · Dec 31, 2025Common Stock (Book)
404.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.26BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
424.29MUSDvs all stocks (USD)
Treasury Stock
46.47MUSDFY2025 · Dec 31, 202552-Week Low
0.7000USDUpdated Jul 19, 202652-Week High
1.72USDUpdated Jul 19, 202652-Week Change
-29.37%vs all stocks
Beta
1.42xvs all stocks
50-Day MA
0.9408USDUpdated Jul 19, 2026200-Day MA
1.15USDUpdated Jul 19, 2026Avg 10-Day Volume
2.56MSharesUpdated Jul 19, 2026Avg 30-Day Volume
4.97MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.1300USDUpdated Jul 19, 2026Other Income / Expense
-12.55MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.62×, lower than 95% of its Medical Devices peers (median 2.69×)Notable
Price-to-book: 0.62Industry median: 2.69Industry P5: 0.66Peers compared: 102
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 12.36Altman Z-Score: -1.32
Financial Health
Altman Z-Score -1.32: distress zoneCritical
Altman Z-Score: -1.32
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Deva Holding A.S.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Cellectis S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Tailin Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Xinguang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Rigetti Computing Inc
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Wave Life Sciences Ltd.
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Spire Global Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated